RedHill Biopharma Reports Results for the Third Quarter of 2015

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. SPCX
2. NVDA
3. NFLX
4. META
5. TSLA
6. ISRG
7. SMCI
8. RTX
9. S
10. COF

Go back to RedHill Biopharma Reports Results for the Third Quarter of 2015

RedHill Biopharma (RDHL) Tops Q3 EPS Views; Announces RIZAPORT Marketing Approval in Germany

November 9, 2015 7:56 AM EST

RedHill Biopharma (NASDAQ: RDHL) reported Q3 EPS of ($0.04), $0.47 better than the analyst estimate of ($0.51).

RedHill also announced, together with IntelGenx Corp., that the Federal Institute for Drugs and Medical Devices of Germany (BfArM) has granted marketing authorization of RIZAPORT (RHB-103) 5mg and 10mg, an oral thin film formulation of rizatriptan benzoate for the treatment of acute migraines.

Over 50 million people in Europe are estimated to be affected by migraines. Approximately 2 million Europeans are prone to migraine attacks every day1. The worldwide migraine market is expected to exceed $2 billion in sales in... More